A hematologist wrestles with how to help leukemia patients make the right treatment choices
By Mikkael Sekeres, MD, MS
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
In my outpatient exam room, we had arrived at that moment of silence that often marks the crossroads of unwelcome news and a difficult decision.
My patient, in his mid-60s, had endured a five-week hospitalization after he learned he had leukemia, a period of time that included expected complications of chemotherapy. Week by week, as he returned to my clinic, he became stronger and gained weight, and color had even returned to his cheeks – markers of vitality that my mother might cite, but that also have relevance for those of us who claim only objective assessments of health.
Unfortunately for my patient, though, the numbers didn’t lie. His blood counts failed to recover, and when we performed a bone marrow biopsy to determine why, the results showed that his leukemia persisted.
“I’m not ready to die yet. I want the chemo,” my patient said. I asked him to take some time to think and to talk it through with his wife and his family. He was resolute though, and we admitted him to the hospital the following day. Two weeks later, he died of an uncontrollable infection, on a breathing tube in the intensive care unit.
I was left wondering, not for the first time in my career, if I had launched someone on a path toward premature death. At the very least, I was guilty of that act of hubris of which oncologists are often accused: giving chemotherapy to a person only days before his death.
Read the full New York Times column by Dr. Sekeres, Director of Cleveland Clinic’s Leukemia Program.
Advertisement
Photo Credit ©Russell Lee
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients